Thursday, August 13, 2026

Indianapolis man sentenced to 30 years in federal prison for armed drug trafficking

Deontai Williams received a 30-year federal prison sentence after being convicted on armed drug trafficking charges involving fentanyl, methamphetamine,and cocaine
X / Twitter
LinkedIn
Print

Deontai Williams, 33, of Indianapolis, was sentenced to 30 years in federal prison with five years of supervised release after a federal jury found him guilty of trafficking fentanyl, methamphetamine, and cocaine; illegally possessing eight firearms as a convicted felon; and possessing those firearms in furtherance of his drug-trafficking crimes. The sentencing was announced on July 22 following the jury’s verdict returned in February.

According to court documents and evidence presented at trial, law enforcement officers executed a search warrant at Williams’ residence on January 17, 2025, while he attended a pretrial hearing in Marion County for unrelated drug charges. Officers discovered drugs including methamphetamine, cocaine base, fentanyl, digital scales, eight firearms, and multiple high-capacity magazines.

Williams’ criminal history includes prior offenses such as assaulting a woman who declined to give him a cigarette by taking her cell phone and punching her in the face. In another case, he physically assaulted a six-year-old child by hitting him with an extension cord and throwing him across a room. He has multiple prior felony convictions including battery resulting in bodily injury to someone under age fourteen, unlawful residential entry, unlawful possession of a firearm by a serious violent felon, and dealing methamphetamine.

“Despite multiple incarcerations and consequent opportunities to change course, Deontai Williams continued to traffic deadly drugs and arm himself illegally. His pattern of violence and criminal behavior put our community at serious risk,” said Tom Wheeler, United States Attorney for the Southern District of Indiana. “Thanks to the hard work of DEA agents and our federal prosecutors, another reckless, violent offender faces the accountability he has long evaded.” Gerald C. Dooley, DEA Assistant Special Agent in Charge, said, “Williams’ history of violence and repeated felony convictions demonstrate a pattern of behavior that has absolutely no regard for the law or the safety of our community. This federal prison sentence ensures that a dangerous individual is removed from our neighborhoods and sends a clear message that armed drug traffickers will face full accountability in federal court.”

The Drug Enforcement Administration investigated this case with assistance from the Metro Drug Task Force. U.S. District Chief Judge James R. Sweeney II imposed the sentence with twenty-five years running consecutive to Williams’ state sentence in Marion County Cause No. 49D31-2206-F2-016856.

The U.S. Attorney for the Southern District of Indiana is responsible for prosecuting federal crimes across sixty southern counties divided into four divisions; it maintains offices both at its headquarters in Indianapolis as well as Evansville; collaborates with local agencies; defends United States interests before courts; serves as chief law enforcement office under Department of Justice oversight, according to the official website.

Filed Under

Share This Story

X / Twitter
LinkedIn
Email
Print

Advertisement

300 × 250

Related

Daily Dispatch

The morning briefing on federal government — delivered to your inbox before 7 AM.

Advertisement

300 × 120

More from Defense

Washington National Guard Continues Statewide Wildfire Response

The Washington National Guard continued deploying air and ground assets across the state on Aug. 10 as multiple wildfires burned simultaneously in the Pacific Northwest. Federal active-duty forces from Joint...

OCC Signals Push to Revive New Bank Charter Applications

The Office of the Comptroller of the Currency announced on Aug. 11 that it will prioritize new bank charter applications as part of a “community bank comeback” initiative. The effort...

FDA Approves First Oral PCSK9 Inhibitor to Lower Cholesterol

The FDA approved the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults on July 17, removing a major barrier to broader use of the most powerful class of...